Drugs / NOX1416
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06402565 | Jun 2024 → Jun 2026 overdue | ulcer of lower limbs | NOxy Health Products, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06020664 | Aug 2023 → Sep 2024 | ulcer of lower limbs | NOxy Health Products, LLC | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOX1416 | “NOX1416 is a foam based gaseous nitric oxide (NO) product where NO is delivered through a microbubble foam.” NCT06020664 ↗ |
| Modality | Other / unclassified | “NOX1416 is a foam based gaseous nitric oxide (NO) product where NO is delivered through a microbubble foam.” NCT06020664 ↗ |
| Route | Topical | “NOX1416 is topically applied directly onto the wound bed” NCT06020664 ↗ |